Rezolute, Inc. Files 8-K: Material Agreement & Officer Changes

TL;DR

Rezolute filed an 8-K for a material agreement and board changes. Big moves happening.

AI Summary

Rezolute, Inc. announced on August 18, 2025, a material definitive agreement and changes in its board and officer composition. The company also disclosed information under Regulation FD and filed financial statements and exhibits. Rezolute, Inc. was formerly known as AntriaBio, Inc. and FITS MY STYLE INC.

Why It Matters

This filing indicates significant corporate actions, including a new material agreement and potential leadership shifts, which could impact the company's strategic direction and operational execution.

Risk Assessment

Risk Level: medium — The filing involves material definitive agreements and changes in officers/directors, which can introduce uncertainty and strategic shifts.

Key Players & Entities

• Rezolute, Inc. (company) — Registrant
• August 18, 2025 (date) — Date of earliest event reported
• AntriaBio, Inc. (company) — Former company name
• FITS MY STYLE INC (company) — Former company name
• Nevada (jurisdiction) — State of incorporation

FAQ

Key Financial Figures

• $0.001 — registered Common Stock, par value $0.001 per share RZLT Nasdaq Capital Market
• $475,000 — t will receive an annual base salary of $475,000, a signing bonus of $65,000, and will b
• $65,000 — salary of $475,000, a signing bonus of $65,000, and will be eligible for annual incent

Filing Documents

• tm2523938d1_8k.htm (8-K) — 30KB
• tm2523938d1_ex99-1.htm (EX-99.1) — 10KB
• 0001104659-25-080473.txt ( ) — 208KB
• rzlt-20250818.xsd (EX-101.SCH) — 3KB
• rzlt-20250818_lab.xml (EX-101.LAB) — 33KB
• rzlt-20250818_pre.xml (EX-101.PRE) — 22KB
• tm2523938d1_8k_htm.xml (XML) — 4KB

01

Item 1.01 Entry into a Material Definitive Agreement.

02

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (c) Election of Chief Commercial Officer. On August 18, 2025, Rezolute, Inc. (the " Company ") appointed Sunil Karnawat, age 58, as Chief Commercial Officer of the Company, Dr. Karnawat brings over two decades of executive leadership experience in the biotech, pharma, medical device, and diagnostics industries. Since 2024, Dr. Karnawat served as Vice President for Cytokinetics Pharmaceuticals. From 2017 through 2024, Dr. Karnawat served in various executive and vice president roles with Ultragenyx Pharmaceuticals in which Dr. Karnawat was involved in leading key commercial functions in launching four ultra-rare disease products, including Crysvita with indications for X-linked Hypophosphatemia and Tumor-induced Osteomalacia. Dr. Karnawat's education includes an MBA from the Wharton School of Business at the University of Pennsylvania, a Ph.D. and an M.S. in Engineering from North Dakota State University, and a B.E. in Civil Engineering from the College of Engineering in Pune, India. In connection with his appointment as Chief Commercial Officer, the Company entered into an employment agreement with Dr. Karnawat (the " Karnawat Employment Agreement "). Under the terms of the Karnawat Employment Agreement, Dr. Karnawat will receive an annual base salary of $475,000, a signing bonus of $65,000, and will be eligible for annual incentive compensation with a target of up 40% of his base salary, subject to performance metrics established by the board. Dr. Karnawat also received 270,000 stock options and 25,000 restricted stock units both subject to vesting and other customary terms. The agreement contains customary confidentiality and intellectual property provisions and may be terminated by either party in accordance with its terms. There are no arrangements or understandings between Dr. Karnawat and any other

01

Item 7.01. Regulation FD Disclosure. On August 20, 2025, Rezolute, Inc. issued a press release announcing the appointment of Dr. Karnawat as our Chief Commercial Officer. The text of the press release is included as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference. The information in Item 7.01 of this Current Report on Form 8-K, including the attached Exhibit 99.1 is being furnished pursuant to Item 7.01 and shall not be deemed to be "filed" for any purpose of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act "), or otherwise under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof and regardless of any general incorporation language in such filings, except to the extent expressly set forth by specific reference in such a filing.

01. Financial Statements

Item 9.01. Financial Statements and Exhibits (d) Exhibits. Exhibit Number Description 99.1 Press Release dated August 20, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. REZOLUTE, INC. DATE: August 20, 2025 By: /s/ Nevan Charles Elam Nevan Charles Elam Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR